Neumora Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

NMRA$0.47-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited, in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$29,283	$38,724	$67,881	$90,875
General and administrative	12,907	15,316	27,173	34,101
Total operating expenses	42,190	54,040	95,054	124,976
Loss from operations	(42,190)	(54,040)	(95,054)	(124,976)
Other income (expense):
Interest income	935	2,250	2,166	5,324
Interest expense	(1,820)	(436)	(3,674)	(436)
Other income (expense), net	(7)	(480)	52	(505)
Total other income (expense)	(892)	1,334	(1,456)	4,383
Net loss before income taxes	(43,082)	(52,706)	(96,510)	(120,593)
Provision for income taxes	—	25	30	130
Net loss	$(43,082)	$(52,731)	$(96,540)	$(120,723)
Other comprehensive loss:
Unrealized loss on marketable securities	—	(12)	—	(77)
Comprehensive loss	$(43,082)	$(52,743)	$(96,540)	$(120,800)
Net loss per share, basic and diluted	$(0.23)	$(0.33)	$(0.53)	$(0.75)
Weighted-average shares outstanding, basic and diluted	185,163	161,691	182,504	161,572

The accompanying notes are an integral part of these condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.